Austedo for Tardive Dyskinesia: every route to paying for it

The routes, in order

1. 1

   Why this drug and this condition are paired

   ... tardive dyskinesia [see Clinical Studies ( 14.

   From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

   Label on openFDA, read 2026-11-10 · receipt

2. 2

   Medicare Part D: the yearly out-of-pocket threshold

   Found in our data
   CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).

   A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.

   CMS Table V-2, read 2026-11-08

3. 3

   Medicare negotiated price

   Found in our data
   CMS lists $4,093.00 for a 30-day supply, effective 2027-01-01.

   The price CMS lists for the drug, not what you pay. What you pay depends on your plan and your cost sharing.

   CMS negotiated prices, read 2026-11-06

4. 4

   Manufacturer and foundation programs

   Not found in our data
   No program in our assistance finder lists this drug.

   That does not mean none exists.

5. 5

   Charitable funds for Tardive Dyskinesia

   Found in our data
   We hold 1 fund for Tardive Dyskinesia: 1 open and 0 not open, read 2026-11-08. Open: Tardive Dyskinesia - Medicare Access from HealthWell Foundation.

   Every fund, with its award level, insurance supported and source, is on the Tardive Dyskinesia page. A fund pays for a condition's costs, not necessarily this drug.

6. 6

   Clinical trial access

   Found in our data
   ClinicalTrials.gov lists 2 recruiting interventional trials that name this ingredient (read 2026-11-07).

   A trial is research, not treatment access for everyone, and a listing is not a recommendation.

   ClinicalTrials.gov, read 2026-11-07 · receipt

Questions